Skip to main content
Premium Trial:

Request an Annual Quote

Almac, Merck KGaA Partner on Cetuximab Markers

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Almac Diagnostics will collaborate with Merck KGaA and the Medical Research Council on a study of potential biomarkers of response to the cancer drug cetuximab (Erbitux).

The partners will use metastatic colon cancer samples from the MRC's COIN trial — a phase III, multicenter, three-arm study of first-line treatment of metastatic colon cancer — to assess the potential biomarkers. Cetuximab has been approved in Europe in combination with standard chemotherapy as a first-line treatment for mCRC in patients with KRAS wildtype tumors.

Craigavon, Northern Ireland-based Almac said that it will conduct quantitative PCR profiling and data analysis of the samples and assess potential biomarkers, beyond KRAS, in the context of combination therapy with cetuximab.

Further terms of the alliance were not disclosed.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.